ArticlePsychopharmacology2026
Relationship between circulating plasma endocannabinoids in adolescents and maternal depressive symptoms.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Longitudinal changes in endocannabinoids and clinical course of adolescent non-suicidal self-injury.Translational psychiatry · 2026Article
- EBPS2023 special issue: Stress, trauma and cannabinoids.Psychopharmacology · 2026Article
- Differential Effects of Adolescent Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Inhibition on Adolescent and Adult Behaviors in Male Rats.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe endocannabinoid signaling system regulates stress and is implicated in depression, with altered circulating endocannabinoid concentrations frequently reported in adults with depression compared to without. Maternal depression is a well-established predictor of depressive symptoms in youth. However, few studies have examined the relationship between circulating endocannabinoids and susceptibility to psychiatric disorders during adolescence, a high-risk period for symptom onset. This study examines associations among adolescent depressive symptoms, maternal depressive symptoms, and circulating endocannabinoids in a heterogenous community sample of adolescents.
methodsThis study reports on 77 adolescents (M ± SD = 13.36 ± 2.19 years, 51.9% female; 41.6% White Non-Hispanic, 41.6% Black Non-Hispanic, 5.2% Hispanic, 9.0% biracial) and their biological mothers. Depressive symptoms were measured in mothers and adolescents using the Beck Depression Inventory and Children's Depression Inventory, respectively. Adolescent plasma concentrations of the endocannabinoids N-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoylglycerol (2-AG) were quantified using liquid chromatography-tandem mass spectrometry.
resultsOver half (58.4%) of adolescents and 15.6% of mothers exceeded clinically significant depression cut-offs. Maternal and adolescent depressive symptoms were not significantly associated (R
conclusionHigher AEA concentrations may serve as a monitoring marker of familial susceptibility for depression during adolescence, including among adolescents with subthreshold symptoms. These results suggest the endocannabinoid system as a potential target for identifying risk and developing interventions during adolescence.
Indexed as
Identifiers
40531314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.